drugset
drugset / Trial / NCT00275080

Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia

NCT00275080 ↗

Phase 1 Completed 80 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with decitabine in treating patients with advanced solid tumors or relapsed or refractory non-Hodgkin's lymphoma, acute myeloid leukemia, acute lymphocytic leukemia, or chronic myelogenous leukemia. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving vorinostat together with decitabine may kill more cancer cells.

Timeline

Start
2006-02
Primary completion
2009-11
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — Intravenous
Subject Vorinostat Small molecule — Oral

Indications

Burkitt lymphoma MALT lymphoma acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(15;17)(q24;q21) acute myeloid leukemia, t(16;16)(p13.1;q22) adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive cancer of unknown primary site chronic lymphocytic leukemia/small lymphocytic lymphoma diffuse large B-cell lymphoma large-cell immunoblastic lymphoma mantle cell lymphoma nodal marginal zone B-cell lymphoma splenic marginal zone lymphoma therapy related acute myeloid leukemia and myelodysplastic syndrome